Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, is set to participate in the Stifel 2023 Virtual Targeted Oncology Days on April 26, 2023, at 1:30 p.m. ET. The presentation will feature CEO James Porter and CFO Alexandra Balcom.

Investors can access a live webcast on the company's website, with an archived version available for 30 days. Nuvalent focuses on developing targeted therapies for cancer, leveraging expertise in chemistry and drug design. Their pipeline includes treatments for ROS1-positive and ALK-positive non-small cell lung cancer, as well as other cancer types. The company aims to offer innovative solutions that address resistance and improve treatment outcomes.

CAMBRIDGE, Mass., April 19, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2023 Virtual Targeted Oncology Days on Wednesday, April 26, 2023, at 1:30 p.m. ET. 

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-stifel-2023-virtual-targeted-oncology-days-301801174.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent participating in the Stifel 2023 Virtual Targeted Oncology Days?

Nuvalent will participate in the Stifel 2023 Virtual Targeted Oncology Days on April 26, 2023, at 1:30 p.m. ET.

Who from Nuvalent will speak at the Stifel 2023 Oncology Days?

CEO James Porter and CFO Alexandra Balcom will represent Nuvalent at the event.

How can investors access the Nuvalent presentation?

Investors can access the live webcast of the presentation on Nuvalent's website, which will be archived for 30 days afterward.

What is Nuvalent's focus in drug development?

Nuvalent focuses on creating precisely targeted therapies for cancer by addressing clinically proven kinase targets.

What types of cancer does Nuvalent's pipeline address?

Nuvalent's pipeline includes lead programs for ROS1-positive and ALK-positive non-small cell lung cancer and therapies for HER2 Exon 20 insertion-positive cancers.